GLP-1 receptor agonists (GLP-1s) and SGLT-2 inhibitors lower the risk of major cardiovascular events like heart attacks and severe liver complications compared to other diabetes treatments, according to data being presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
FDA approves Biostar’s Phase II/III plans with utidelone injectable for NSCLC – Pharmaceutical Technology
Lung cancer is one of the Utidelone applications currently being studied. Source: Shutterstock / Kateryna Kon. Synthetic biology biopharma Biostar Pharma announced is ready to